Company Description
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide.
The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta/Venclyxto to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma.
It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic to treat neurologic diseases; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duopa and Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; and Qulipta for episodic and chronic migraine, as well as other neuroscience products.
In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products.
Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation.
The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
| Country | United States |
| Founded | 2012 |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| Employees | 55,000 |
| CEO | Robert Michael |
Contact Details
Address: 1 North Waukegan Road North Chicago, Illinois 60064-6400 United States | |
| Phone | 847 932 7900 |
| Website | abbvie.com |
Stock Details
| Ticker Symbol | ABBV |
| Exchange | NYSE |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001551152 |
| CUSIP Number | 00287Y109 |
| ISIN Number | US00287Y1091 |
| Employer ID | 32-0375147 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Robert A. Michael CPA | Chief Executive Officer and Chairman of the Board |
| Scott T. Reents | Executive Vice President and Chief Financial Officer |
| Dr. Azita Saleki-Gerhardt Ph.D. | Executive Vice President and Chief Operating Officer |
| Jeffrey Ryan Stewart | Executive Vice President and Chief Commercial Officer |
| Dr. Roopal Thakkar M.D. | Executive Vice President of Research and Development and Chief Scientific Officer |
| Elizabeth Shea | Senior Vice President of Investor Relations |
| Perry C. Siatis | Executive Vice President, General Counsel and Secretary |
| Demetris D. Crum | Executive Vice President and Chief Human Resources Officer |
| Wulff-Erik von Borcke | Senior Vice President and President of Oncology |
| Dr. Nicholas J. Donoghoe M.D. | Executive Vice President and Chief Business and Strategy Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 22, 2025 | 144 | Filing |
| Aug 21, 2025 | 144 | Filing |
| Aug 12, 2025 | 144 | Filing |
| Aug 8, 2025 | 144 | Filing |
| Aug 5, 2025 | 144 | Filing |
| Aug 4, 2025 | 10-Q | Quarterly Report |
| Jul 31, 2025 | 8-K | Current Report |
| Jul 11, 2025 | 3 | Initial statement of beneficial ownership of securities |
| Jul 7, 2025 | SCHEDULE 13G/A | Filing |
| Jul 3, 2025 | 8-K | Current Report |